ROBO Global®
Healthcare Technology and Innovation ETF
Schedule of Investments
July 31, 2024 (Unaudited)
| Description | Shares | Fair Value | ||||||
| COMMON STOCK†† – 99.9% | ||||||||
| China – 1.1% | ||||||||
| Consumer Staples – 1.1% | ||||||||
| JD Health International* | 231,050 | $ | 643,284 | |||||
| Germany – 1.4% | ||||||||
| Health Care – 1.4% | ||||||||
| Siemens Healthineers | 15,466 | 830,595 | ||||||
| Italy – 1.7% | ||||||||
| Health Care – 1.7% | ||||||||
| DiaSorin | 8,844 | 966,578 | ||||||
| Japan – 2.5% | ||||||||
| Health Care – 2.5% | ||||||||
| PeptiDream* | 45,600 | 840,415 | ||||||
| Terumo | 32,800 | 589,903 | ||||||
| 1,430,318 | ||||||||
| Luxembourg – 1.5% | ||||||||
| Health Care – 1.5% | ||||||||
| Eurofins Scientific | 14,181 | 841,533 | ||||||
| Netherlands – 1.7% | ||||||||
| Health Care – 1.7% | ||||||||
| Koninklijke Philips* | 34,764 | 981,080 | ||||||
| Switzerland – 4.9% | ||||||||
| Health Care – 4.9% | ||||||||
| CRISPR Therapeutics* | 15,065 | 863,074 | ||||||
| Lonza Group | 1,555 | 1,037,668 | ||||||
| Tecan Group | 2,463 | 915,528 | ||||||
| 2,816,270 | ||||||||
| United Kingdom – 1.3% | ||||||||
| Health Care – 1.3% | ||||||||
| Smith & Nephew PLC | 51,016 | 735,877 | ||||||
| United States – 83.8% | ||||||||
| Health Care – 81.3% | ||||||||
| Abbott Laboratories | 7,552 | 800,059 | ||||||
| Agilent Technologies | 6,333 | 895,486 | ||||||
| Align Technology* | 3,083 | 714,886 | ||||||
| Alnylam Pharmaceuticals* | 3,244 | 770,320 | ||||||
| Arrowhead Pharmaceuticals* | 38,119 | 1,088,679 | ||||||
| Artivion* | 35,655 | 968,033 | ||||||
| Axogen* | 142,130 | 1,247,902 | ||||||
| Azenta* | 15,608 | 972,222 | ||||||
| Baxter International | 17,850 | 639,387 | ||||||
| Becton Dickinson | 2,986 | 719,805 | ||||||
| BioMarin Pharmaceutical* | 8,474 | 714,612 | ||||||
| Bio-Rad Laboratories, Cl A* | 3,022 | 1,022,524 | ||||||
| Boston Scientific* | 12,528 | 925,569 | ||||||
| Bristol-Myers Squibb | 16,959 | 806,570 | ||||||
| CareDx* | 49,501 | 989,525 | ||||||
| Catalent* | 16,250 | 964,275 | ||||||
| Description | Shares | Fair Value | ||||||
| United States – continued | ||||||||
| Health Care – continued | ||||||||
| Charles River Laboratories International* | 4,614 | $ | 1,126,276 | |||||
| CONMED | 8,688 | 599,820 | ||||||
| Danaher | 3,674 | 1,017,992 | ||||||
| DexCom* | 6,932 | 470,128 | ||||||
| Edwards Lifesciences* | 9,724 | 613,098 | ||||||
| Exact Sciences* | 17,538 | 801,136 | ||||||
| Fulgent Genetics* | 36,113 | 864,184 | ||||||
| GE HealthCare Technologies | 10,123 | 856,709 | ||||||
| Globus Medical, Cl A* | 10,042 | 722,622 | ||||||
| GRAIL* | 1,395 | 21,460 | ||||||
| Guardant Health* | 34,556 | 1,213,952 | ||||||
| Health Catalyst* | 80,013 | 589,696 | ||||||
| Hologic* | 10,705 | 873,635 | ||||||
| Illumina* | 8,366 | 1,025,672 | ||||||
| Incyte* | 14,401 | 937,073 | ||||||
| Integra LifeSciences Holdings* | 30,236 | 750,155 | ||||||
| Intuitive Surgical* | 2,374 | 1,055,505 | ||||||
| IQVIA Holdings* | 4,137 | 1,018,654 | ||||||
| iRhythm Technologies* | 7,922 | 683,273 | ||||||
| Masimo* | 5,370 | 574,483 | ||||||
| Medpace Holdings* | 1,926 | 736,734 | ||||||
| Moderna* | 6,300 | 751,086 | ||||||
| Natera* | 8,910 | 912,295 | ||||||
| Novocure* | 38,706 | 881,336 | ||||||
| Omnicell* | 25,668 | 749,762 | ||||||
| Penumbra* | 5,036 | 841,465 | ||||||
| QIAGEN | 18,997 | 845,177 | ||||||
| QuidelOrtho* | 18,901 | 742,620 | ||||||
| Regeneron Pharmaceuticals* | 910 | 982,063 | ||||||
| Revvity | 8,574 | 1,076,980 | ||||||
| Roche Holding | 2,766 | 898,066 | ||||||
| STAAR Surgical* | 24,601 | 1,014,791 | ||||||
| Stryker | 2,837 | 928,976 | ||||||
| Teladoc Health* | 51,208 | 482,891 | ||||||
| Thermo Fisher Scientific | 1,706 | 1,046,358 | ||||||
| Twist Bioscience* | 14,922 | 832,797 | ||||||
| United Therapeutics* | 2,414 | 756,282 | ||||||
| Veeva Systems, Cl A* | 3,544 | 680,200 | ||||||
| Veracyte* | 36,701 | 880,824 | ||||||
| Vertex Pharmaceuticals* | 2,053 | 1,017,713 | ||||||
| 47,113,793 | ||||||||
| Information Technology – 1.6% | ||||||||
| Novanta* | 5,080 | 920,394 | ||||||
ROBO Global®
Healthcare Technology and Innovation ETF
Schedule of Investments
July 31, 2024 (Unaudited)
| Description | Shares | Fair Value | ||||||
| United States – continued | ||||||||
| Materials – 0.9% | ||||||||
| Ginkgo Bioworks Holdings* | 1,358,485 | $ | 516,224 | |||||
| 48,550,411 | ||||||||
| Total Common Stock | ||||||||
| (Cost $68,254,855) | 57,795,946 | |||||||
| SHORT-TERM INVESTMENT – 0.0% | ||||||||
| Invesco Government & Agency Portfolio, Institutional Class, 5.22%(A) | 11,574 | 11,574 | ||||||
| Total Short-Term Investment | ||||||||
| (Cost $11,574) | 11,574 | |||||||
| Total Investments - 99.9% | ||||||||
| (Cost $68,266,429) | $ | 57,807,520 | ||||||
Percentages based on Net Assets of $57,849,087.
| * | Non-income producing security. |
| †† | Industries are utilized for compliance purposes, whereas broad sectors are utilized for reporting. |
| (A) | The rate shown is the 7-day effective yield as of July 31, 2024. |
Cl – Class
PLC – Public Limited Company
ROB-QH-001-2200